Resource Type

Journal Article 107

Conference Videos 2

Conference Information 1

Year

2023 10

2022 12

2021 14

2020 5

2019 14

2018 7

2017 4

2016 4

2015 1

2014 1

2013 2

2012 7

2011 2

2010 5

2009 10

2008 2

2007 5

1999 1

open ︾

Keywords

immunotherapy 16

PD-L1 4

cancer immunotherapy 4

hepatocellular carcinoma 4

immune checkpoint inhibitor 4

tumor 4

Cancer 3

Immunotherapy 3

PD-1 3

angiogenesis 3

metastasis 3

CAR T cells 2

Colorectal cancer 2

Exosomes 2

Point of care 2

Tumor 2

autoimmune 2

cancer stem cell 2

cancer therapy 2

open ︾

Search scope:

排序： Display mode:

Immunometabolism: a new dimension in immunotherapy resistance

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 585-616 doi: 10.1007/s11684-023-1012-z

Abstract: inhibitors (ICIs) have demonstrated unparalleled clinical responses and revolutionized the paradigm of tumorAlthough dysregulated metabolism has long been adjudged as a hallmark of tumor, it is now increasinglyaccepted that metabolic reprogramming is not exclusive to tumor cells but is also characteristic ofthe resistance and ameliorate existing ICI immunotherapy, whose crux might be to ascertain synergisticHerein, we elaborate potential mechanisms underlying immunotherapy resistance from a novel dimension

Keywords： immune cell     immunometabolism     metabolic reprogramming     immunotherapy     resistance     tumor microenvironment    

HTML PDF Collect

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

Frontiers of Medicine 2007, Volume 1, Issue 1,   Pages 11-19 doi: 10.1007/s11684-007-0003-9

Abstract: A remarkable advance in tumor immunology during the last decade is the elucidation of the antigenic basisof tumor recognition and destruction.these antigens, cancer/testis antigen (CT antigen) is considered to be the most promising target for immunotherapySuccessful immunotherapy of tumors requires understanding of the natural relationship between the immunesystem and tumor in the status of differentiation, invasion and maturation.

Keywords： development     conventional     identification     elucidation     Successful immunotherapy    

HTML PDF Collect

Natural killer cell lines in tumor immunotherapy

Min Cheng, Jian Zhang, Wen Jiang, Yongyan Chen, Zhigang Tian

Frontiers of Medicine 2012, Volume 6, Issue 1,   Pages 56-66 doi: 10.1007/s11684-012-0177-7

Abstract: Current NK cell-based cancer immunotherapy is aimed at overcoming NK cell paralysis through several potentialgenetically modifying NK cell lines by increasing their expression of cytokines and engineering chimeric tumorIn this review, NK cells in tumor immunotherapy are discussed, and a list of therapeutic NK cell lines

Keywords： natural killer cell     natural killer cell line     tumor immunotherapy     genetic modification    

HTML PDF Collect

Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

Kai Shi, Matthew Haynes, Leaf Huang

Frontiers of Chemical Science and Engineering 2017, Volume 11, Issue 4,   Pages 676-684 doi: 10.1007/s11705-017-1640-4

Abstract: Specifically, reversing the immune-suppressive effects of the tumor microenvironment, mediated by a varietyimplemented various nano-vaccines based on the lipid-coated calcium phosphate platform for combined immunotherapy

Keywords： vaccine     nanoparticle     tumor     immunotherapy     microenvironment    

HTML PDF Collect

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellSingle-cell RNA sequencing results were obtained from core needle biopsy tumor samples collected fromM2-subtype macrophages were significantly involved in both in vivo and in vitro anti-tumorImmunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansionThus, our findings provided a clinical rationale for targeting tumor microenvironments and reprogramming

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment     tumor-associated macrophage     metabolism    

HTML PDF Collect

-1BBL expressed by eukaryotic cells activates immune cells and suppresses the progression of murine tumor

Hui QIU, Hui ZHANG, Zuohua FENG

Frontiers of Medicine 2009, Volume 3, Issue 1,   Pages 20-25 doi: 10.1007/s11684-009-0006-9

Abstract: The function of 4-1BB/4-1BBL expressed by the immune cells has been the focus for many tumor immunotherapyIn this study, 4-1BBL was expressed in non-immune cells and non-tumor cells, and the role of 4-1BBL inlymphocyte activation and tumor suppression was investigated.the number of CD8 T cells in the peri-tumoral tissue increased markedly, and the growth rate of the tumorThis therapeutic method may provide a promising approach for tumor immunotherapy.

Keywords： 4-1BB ligand     tumor immunotherapy     tumor microenvironment    

HTML PDF Collect

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Frontiers of Medicine 2012, Volume 6, Issue 2,   Pages 122-133 doi: 10.1007/s11684-012-0193-7

Abstract: As a typical virus and inflammation-associated cancer, both host immune response and tumor microenvironmentIn addition, we examine the potential of immunotherapy and strategies targeting various components ofthe tumor microenvironment, as well as novel molecular and cellular targets in HCC such as cancer stem

Keywords： hepatocellular carcinoma     molecular classification     molecular targeted therapies     tumor microenvironment     immunotherapy    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: However, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyThe simultaneous expression of target antigens by healthy organs and tumor cells is partly responsibleAlongside targeting tumor-specific antigens, targeting the aberrantly glycosylated glycoforms of tumor-associatedantigens can also minimize the off-tumor effects of CAR-T therapies.Tn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation    

HTML PDF Collect

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 307-321 doi: 10.1007/s11684-022-0927-0

Abstract: inhibitors, such as PD-1/PD-L1 and CTLA-4, has played an important role in the development of cancer immunotherapy

Keywords： tumor immunotherapy     immune checkpoint inhibitor     antibiotics     gut microbiota     drug–drug interaction    

HTML PDF Collect

Prospect of Medical Disruptive Technologies

Li Yongjie, Yang Juntao, Du Jian

Strategic Study of CAE 2018, Volume 20, Issue 6,   Pages 64-68 doi: 10.15302/J-SSCAE-2018.06.010

Abstract: This paper mainly analyzes and evaluates five technical directions in tumor immunotherapy, gene editing

Keywords： medical technology     disruptive technology     tumor immunotherapy     gene editing    

HTML PDF Collect

Prospects of immunotherapy for cancer

Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 1-2 doi: 10.1007/s11684-019-0691-y

Abstract:
HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TEpidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in various

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

Frontiers of Medicine 2011, Volume 5, Issue 4,   Pages 323-332 doi: 10.1007/s11684-011-0172-4

Abstract:
HTML PDF Collect

Heterogeneity of the tumor immune microenvironment and clinical interventions

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 617-648 doi: 10.1007/s11684-023-1015-9

Abstract: Heterogeneity of the tumor immune microenvironment and clinical interventions

Keywords： Heterogeneity tumor immune    

HTML PDF Collect

Challenges of NK cell-based immunotherapy in the new era

Fang Fang, Weihua Xiao, Zhigang Tian

Frontiers of Medicine 2018, Volume 12, Issue 4,   Pages 440-450 doi: tzg@ustc.edu.cn

Abstract:

Natural killer cells (NKs) have a great potential for cancer immunotherapy because they can rapidly

Keywords： natural killer cells     immunotherapy     adoptive transfer     genetic modification     immune checkpoint inhibitor    

HTML Collect

Title Author Date Type Operation

Immunometabolism: a new dimension in immunotherapy resistance

Journal Article

Developing effective tumor vaccines: basis, challenges and perspectives

XU Qingwen, CHEN Weifeng

Journal Article

Natural killer cell lines in tumor immunotherapy

Min Cheng, Jian Zhang, Wen Jiang, Yongyan Chen, Zhigang Tian

Journal Article

Nanovaccines for remodeling the suppressive tumor microenvironment: New horizons in cancer immunotherapy

Kai Shi, Matthew Haynes, Leaf Huang

Journal Article

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphoma

Journal Article

-1BBL expressed by eukaryotic cells activates immune cells and suppresses the progression of murine tumor

Hui QIU, Hui ZHANG, Zuohua FENG

Journal Article

Translational medicine in hepatocellular carcinoma

Qiang Gao, Yinghong Shi, Xiaoying Wang, Jian Zhou, Shuangjian Qiu, Jia Fan

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy

Journal Article

Prospect of Medical Disruptive Technologies

Li Yongjie, Yang Juntao, Du Jian

Journal Article

Prospects of immunotherapy for cancer

Zhinan Chen

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Dendritic cell vaccines in cancer immunotherapy: from biology to translational medicine

Hongmei Xu, Xuetao Cao

Journal Article

Heterogeneity of the tumor immune microenvironment and clinical interventions

Journal Article

Challenges of NK cell-based immunotherapy in the new era

Fang Fang, Weihua Xiao, Zhigang Tian

Journal Article